| Literature DB >> 35647009 |
Florian N Loch1, Carsten Kamphues1, Katharina Beyer1, Frederick Klauschen2, Christian Schineis1, Benjamin Weixler1, Johannes C Lauscher1, Marc Dorenbeck1, Christian Bayerl3, Rolf Reiter3,4.
Abstract
Background: Despite the success of standard magnetic resonance enterography (MRE) in detecting Crohn's disease (CD), characterization of strictures and, thus, therapy guidance is still limited. The aim of the study was to determine diagnostic accuracy of MRE in detecting or ruling out active inflammation and identifying fibrotic lesions in patients with terminal ileal CD with histopathology as reference.Entities:
Keywords: Crohn’s disease; active inflammation; acute inflammation score; fibrosis; magnetic resonance enterography
Year: 2022 PMID: 35647009 PMCID: PMC9136038 DOI: 10.3389/fsurg.2022.872596
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Flowchart of patient recruitment. The process of patient selection with the respective number of patients for each exclusion criterion is shown.
Demographic and clinical characteristics of the patient population investigated.
| Patients | |
|---|---|
| Age | |
| Median age (years) | 32 |
| Age range (years) | 19–79 |
| Sex | |
| Female | 41 (61.2%) |
| Male | 26 (38.8%) |
| Time between initial diagnosis and surgery | |
| Median (years) | 4 |
| Range (years) | 0–32 |
| Medical therapy at time of surgery | |
| Corticosteroids | |
| Budesonide | 6 (9.0%) |
| Budesonide and mesalazin | 3 (4.5%) |
| Prednisone | 8 (11.9%) |
| Prednisone and mesalazin | 2 (3.0%) |
| Immunosuppressive agents (azathioprine, Mtx) | 4 (6.0%) |
| Antibodies (adalimumab, infliximab, ustekinumab, vedolizumab) | 10 (14.9%) |
| Corticosteroids and immunosuppressive agents | 1 (1.49%) |
| Corticosteroids and antibodies | 2 (3.0%) |
| Immunosuppressive agents and antibodies | 7 (10.4%) |
| Corticosteroids and immunosuppressive agents and antibodies | 5 (7.5%) |
| None | 19 (28.4%) |
| Time between MRI and surgery | |
| Median (days) | 9 |
| Range (days) | 0 (same day surgery)–86 |
| Histopathological characteristics | |
| Active inflammatory terminal ileal CD | 64 (95.5%) |
| Non-active inflammatory terminal ileal CD with chronic changes only | 3 (4.5%) |
Figure 2Histogram of acute inflammation scores. Histopathological findings are indicated by different colors: red – no signs of acute inflammation; turquoise: the presence of acute inflammation.
Figure 3Representative cases. Upper row: A 37-year-old man with ileal Crohn’s disease and an increased acute inflammation score (AIS) of 8.63. The terminal ileum (arrows) shows the following imaging features of acute inflammation: (A) mural thickening of up to 9 mm; (B,C) a marked increase in the signal of the bowel wall consistent with edema; and (D) a marked contrast enhancement. Histopathology revealed severe ulcerative ileitis with active inflammation. Lower row: A 37-year-old man with ileal Crohn’s disease and a decreased AIS of 2.73. The terminal ileum (arrowheads) is characterized by the following findings: (E) no measurable mural thickening; (F,G) minor increase in the signal of the bowel wall indicating edema; and (H) minor contrast enhancement. Histopathology revealed focally dilated ileal wall with stromal fibrosis and no active inflammation. Note that supplementary contrast-enhanced images are shown to provide a comprehensive case overview, although they are not a part of the AIS assessment. HASTE, half-Fourier acquisition single-shot turbo-spin-echo sequence; FS, fat saturation; C+, contrast enhancement.